Skip to content

Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation

Major Depression | Anxiety Disorders | Major Depressive Disorder | Obsessive Compulsive Disorder...

The purpose of this study is to identify and validate a panel of genetic markers associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioural activation in children and adolescents with major depressive disorder (MDD), anxiety disorders, or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    6 to 17

Participation Criteria

Inclusion criteria: Participants will be eligible for participation if all of the following are true.

* Resident of Manitoba
* Age, 6 - 17 years
* Diagnosis of major depressive disorder (MDD), anxiety disorder, or obsessive-compulsive disorder (OCD)
* Current or past history of selective serotonin reuptake inhibitor (SSRI), e.g., Citalopram \[Celexa\], Escitalopram \[Cipralex\], Fluoxetine \[Prozac\], Fluvoxamine \[Luvox\], Sertraline \[Zoloft\], Paroxetine \[Paxil/Plaxil CR\]) therapy
* \[Cases Only\] Have experienced behavioural side effects after taking an SSRI that resolved after reducing the dose or discontinuation of the drug
* \[Controls Only\] Did not experience any side effects after taking an SSRI for eight (8) continuous weeks

Exclusion criteria: Participants will be excluded from participation if any of the following are true.

* Inability of parent/legal guardian/mature minors to give informed consent
* Inability of the child (6 - 13 years) to give informed assent
* Unwillingness of the child to provide a saliva sample for genetic analysis
* Current, past, or suspected diagnosis of attention deficit hyperactivity disorder (combined or hyperactive type), oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, pervasive developmental disorder
* History of liver or bone marrow (hematopoietic cell) transplant.

Study Location

Shared Health Facilities
Shared Health Facilities
Winnipeg, Manitoba
Canada

Contact Study Team

Primary Contact

Abdullah Al Maruf, PhD, M.Pharm., B.Pharm

[email protected]
204-318-2575
University of Manitoba College of Pharmacy
University of Manitoba College of Pharmacy
Winnipeg, Manitoba
Canada

Contact Study Team

Primary Contact

Abdullah Al Maruf, PhD, M.Pharm, B.Pharm

[email protected]
204-318-2575
Backup Contact

Mahin Hasan, MSc, BSc

[email protected]
Backup Contact

Abdullah Al Maruf, PhD, M.Pharm, B.Pharm

Study Sponsored By
University of Manitoba
Participants Required
More Information
Study ID: NCT06763081